Note: This education in not intended for any type of board certification but is instead a supplemental education for physicians that care for patients with diabetes (not to replace the patient's endocrinologist who is managing that patient's diabetes care).
Introduction and Instructions
Thank you for your interest in Comprehensive Care for Persons with Diabetes: A Certificate Program! This course has been designed in partnership between endocrinologists and family physicians to provide a holistic course on diabetes care and management. Through this 12-part interactive course, you will learn innovative approaches to caring for persons with diabetes and improving their outcomes and quality of life.
For each module, you will first complete a short pre-test to gauge your current knowledge and competency levels. Then you will complete an interactive module that should take about 75 minutes to finish. Once the module has been completed, you will take a short post-test to indicate the enhancements to your knowledge and competency.
You will repeat this for all 12 modules. Once you have completed all 12, you will have access to a comprehensive final exam covering content from all 12 modules. You must get a 70% or higher on this exam to obtain your certificate, and you will have 3 attempts. After successfully completing the exam, you will receive your certificate and access to various references and resources.
The entire course, including the final exam, has 15.00 AMA PRA Category 1 credits, 15.00 ABIM MOC points, and 15.00 AOA Category 1-A CME hours available. Each module is expected to take around 75 minutes to complete for a total of approximately 15 contact hours plus the final exam. Partial credit will not be awarded.
Course Outline:
- Pre-test for module (repeat for modules 1-12)
- Interactive module (repeat for modules 1-12)
- Post-test for module (repeat for modules 1-12)
- Final exam (must achieve 70% or higher to obtain certificate)
- Certificate and resources
Note that you have one year from the date of access to complete the course content and final exam, through 12/31/2024. If you do not complete the material and exam within that year, you will have to repurchase the course. Once the content has been completed, you will retain access to the course through its expiration on 12/31/2024.
By the end of this module, you should be able to:
- Identify non-insulin antihyperglycemic agents presently available for treatment of individuals with type 2 diabetes.
- Compare and contrast benefits and risks of non-insulin antihyperglycemic agents including those not specifically related to glucose lowering.
- Select appropriate antihyperglycemic agents for individual patients based on matching characteristics of medications and patients’ needs.
Faculty Disclosures:
Lawrence Blonde, MD, FACP, MACE
Ochsner Medical Center
New Orleans, LA
Disclosures: Consultant - Corcept Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Lyndra Therapeutics, Merck, Novo Nordisk, Salix Pharmaceuticals, Sanofi.
To ask a question of this presenter please send an email to elearning@acofp.org with the subject line indicating both the presenter and module names.
Lawrence Blonde, MD, FACP, MACE
Ochsner Medical Center
New Orleans, LA
Disclosures:
- Consultant: Corcept Therapeutics;
- Gilead Sciences, Inc.;
- Janssen Pharmaceuticals, Inc;
- Lyndra Therapeutics; Merck; Novo Nordisk;
- Salix Pharmaceuticals; Sanofi
The American College of Osteopathic Family Physicians (ACOFP) and the Endocrine Society staff associated with the development of this CME activity reported no relevant financial relationships.
The American College of Osteopathic Family Physicians (ACOFP) and the Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter.
Key:
Complete
Next
Failed
Available
Locked